1. Home
  2. RMI vs EDIT Comparison

RMI vs EDIT Comparison

Compare RMI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RMI
  • EDIT
  • Stock Information
  • Founded
  • RMI 2018
  • EDIT 2013
  • Country
  • RMI United States
  • EDIT United States
  • Employees
  • RMI N/A
  • EDIT N/A
  • Industry
  • RMI Finance/Investors Services
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RMI Finance
  • EDIT Health Care
  • Exchange
  • RMI Nasdaq
  • EDIT Nasdaq
  • Market Cap
  • RMI 95.7M
  • EDIT 99.9M
  • IPO Year
  • RMI N/A
  • EDIT 2016
  • Fundamental
  • Price
  • RMI $15.47
  • EDIT $1.22
  • Analyst Decision
  • RMI
  • EDIT Buy
  • Analyst Count
  • RMI 0
  • EDIT 14
  • Target Price
  • RMI N/A
  • EDIT $8.08
  • AVG Volume (30 Days)
  • RMI 17.4K
  • EDIT 2.7M
  • Earning Date
  • RMI 01-01-0001
  • EDIT 02-26-2025
  • Dividend Yield
  • RMI 7.28%
  • EDIT N/A
  • EPS Growth
  • RMI N/A
  • EDIT N/A
  • EPS
  • RMI N/A
  • EDIT N/A
  • Revenue
  • RMI N/A
  • EDIT $61,759,000.00
  • Revenue This Year
  • RMI N/A
  • EDIT N/A
  • Revenue Next Year
  • RMI N/A
  • EDIT N/A
  • P/E Ratio
  • RMI N/A
  • EDIT N/A
  • Revenue Growth
  • RMI N/A
  • EDIT 150.95
  • 52 Week Low
  • RMI $13.05
  • EDIT $1.12
  • 52 Week High
  • RMI $17.37
  • EDIT $11.58
  • Technical
  • Relative Strength Index (RSI)
  • RMI 54.54
  • EDIT 34.85
  • Support Level
  • RMI $15.34
  • EDIT $1.17
  • Resistance Level
  • RMI $15.54
  • EDIT $1.29
  • Average True Range (ATR)
  • RMI 0.16
  • EDIT 0.11
  • MACD
  • RMI 0.07
  • EDIT 0.04
  • Stochastic Oscillator
  • RMI 90.45
  • EDIT 22.22

About RMI RiverNorth Opportunistic Municipal Income Fund Inc.

RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: